The CliniSciences Group Letter

The CliniSciences Group wishes you a very happy new year 2025!

Dear readers, 

After a year 2024 rich in projects, we are delighted to present to you CliniSciences' initiatives for the year 2025, reflecting our constant commitment to research and diagnostics. 

We are particularly proud to announce the  imminent publication of the results of a clinical study promoted by Limoges University Hospital on Oncogramme® (CE/IVD) , our functional diagnostic test for metastatic colorectal cancer. These results will enable us to accelerate the deployment of Oncogramme®, in France as well as on a European and international scale. 

In addition,  the acceleration of patient enrolment in our other clinical study, ONCOG1 , promoted by our subsidiary Oncomedics and conducted in collaboration with the Saint-Joseph Hospital in Marseille, illustrates our determination to offer this technology to all oncologists. This test is an invaluable tool to help choose the the right treatments for their patients with metastatic colorectal cancer. 

The year 2024 was also marked by major investments , notably our participation in the capital increase of Genexpath, a Rouen-based company offering CE/IVD marked kits for the diagnosis of sarcomas (SarcomaFusion) and lymphomas (LymphoSign), as well as in X'Prochem and Sirius NeoSight, a Lyon-based company specializing in the study of circulating tumor cells. These strategic collaborations underline our commitment to diversifying our offerings to better meet the ever-changing needs of oncology diagnostics and production methods. 

Finally, CliniSciences affirms its role as a committed player, attentive to market developments, by actively seeking  opportunities for commercial partnerships and strategic investments  in the fields of oncology, biomanufacturing and preclinical research. 

Our ambition is to maintain a continuous dynamic of innovation and to play a key role in the advancement of medical sciences across the 15 European countries where we operate, while strengthening our teams each year. 

Wishing you the best for 2025.

Tushendan Rasiah

CEO CliniSciences Group

News from our PHRCI clinical study

News from the ONCOG1 study (Innovation Package) 

This randomized clinical study of Oncogramme® Metastatic Colorectal Cancer (mCRC) is being conducted by the Limoges University Hospital, and more specifically the department of Professor Mathonnet, in collaboration with Oncomedics and with the partnership of 13 French hospital centers. 

Follow-up data from the 256 patients  in this clinical study are currently being analyzed, with final results expected in 2025.  

The treatments analyzed within the framework of the Oncogramme® CRCm are the following: Folfirinox, Folfox, Folfiri and 5FU + Folinic Acid.

This randomized clinical study of Oncogramme® is being conducted by the Saint-Joseph Hospital in Marseille, and more specifically the department of Dr. Perrier, in collaboration with Oncomedics, for patients with metastatic colorectal cancer (mCRC). ONCOG1 follows Oncomedics' obtaining of the Innovation Package in 2019, supported by the HAS and the Ministry of Health.

The ONCOG1 study aims to enroll  450 patients , for whom inclusions are currently ongoing. The treatments analyzed in this clinical study are not only chemotherapies or combinations of chemotherapies (Folfirinox, Folfox, Folfiri and 5FU + Folinic Acid,) but also targeted therapies prescribed to treat metastatic colorectal cancer. The primary completion date of this study is scheduled for the end of 2025, with an estimated date of final completion in December 2026. 

A look back at the inauguration of the new Oncomedics premises

CliniSciences selected for the 4th edition of the ETIncelles 2024 program!

It was Friday October 18, and for us it was one of the highlights of the year! The inaugural day of Oncomedics' new premises was an opportunity for the CliniSciences Group subsidiary to showcase its expertise in medical innovation, and in particular the Oncogram®.

The program for the event included a tour of the laboratories, meetings with all the healthtech players and entrepreneurs in the Limousin region, and two conferences on the challenges of financing the sector and innovative companies in the region.

Many thanks to the more than 70 participants, as well as to the speakers at the round tables: Olivier Chabanon, Managing Director of France Biotech; Magali Granger, President of Strat'Up Visor; Bruno Génin, entrepreneur and investor in the healthcare sector; Emile Roger Lombertie, Mayor of Limoges; Hugo de Gentile, impact entrepreneur; Laure Sandoval, President of Sanodev; and Mehdi Hammouche, Deputy Managing Director of Limoges Métropole.

CliniSciences Group is proud to announce its selection for the 4ᵉ edition of the ETIncelles 2024 program, a prestigious initiative supported by the Direction Générale des Entreprises. This recognition highlights our commitment to growth, innovation and our ambition to become an intermediate-sized company (ETI). 

Being selected as one of these 46 companies is recognition of our hard work and strategic vision. This opportunity will enable us to strengthen our development, both in France and internationally, and to continue innovating to meet the growing needs of scientific and medical research.

An unforgettable weekend in Marrakech for the CliniSciences Group

In November 2024, members of the CliniSciences group gathered in Marrakech for an exceptional weekend. This event brought together almost 100 employees from our various European offices, offering a unique moment of sharing, discovery and conviviality.

The weekend provided an opportunity for our teams to meet in a warm and exotic setting. These moments of exchange strengthened the bonds between our employees, creating an atmosphere of mutual support and collaboration that reflects our daily values.

This highlight would not have been possible without the warm welcome extended by our Moroccan office.

On the program:

• Immersive activities to discover the local culture;
• Relaxing moments for sharing between different members of the group.

This weekend in Marrakech embodied the strength of our group: a community of committed talents, driven by a spirit of innovation and collaboration.